Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non–Small Cell Lung Cancer

Tamura, Tomoki; Akimoto, Etsuko; Matsumoto, Chiaki; Mori, Syunta; Nishi, Tatuya; Kudo, K.; Kuyama, S.

doi:10.1016/j.jtho.2018.04.026

Cited by 21 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sensitization to melanin-related antigens has been proposed as the aetiology of this syndrome, with PD-1-positive T cell infiltration of the uvea being involved in anterior and posterior uveitis [113][114][115] . VKH syndrome has been reported in patients receiving ipilimumab, pembrolizumab and in those receiving nivolumab [116][117][118] . Ulcerative keratitis, idiopathic orbital inflammation, choroidal neovascularization and melanoma-associated retinopathy have also all been described 119 .…”

Section: Ocular Iraesmentioning

confidence: 99%

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Martins

Latifyan

Sykiotis³

et al. 2019

Nat Rev Clin Oncol

1,570

1,183

View full text Add to dashboard Cite

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTL A-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for these agents continue to expand across malignancies and disease settings, thus reshaping many of the previous standard-of-care approaches and bringing new hope to patients. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), which are often distinctly different from the classical chemotherapy-related toxicities. Owing to the growing use of ICIs in oncology, clinicians will increasingly be confronted with common but also rare irAEs; hence, awareness needs to be raised regarding the clinical presentation, diagnosis and management of these toxicities. In this Review, we provide an overview of the various types of irAEs that have emerged to date. We discuss the epidemiology of these events and their kinetics, risk factors, subtypes and pathophysiology, as well as new insights regarding screening and surveillance strategies. We also highlight the most important aspects of the management of irAEs.

show abstract

Section: Ocular Iraesmentioning

confidence: 99%

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Martins

Latifyan

Sykiotis³

et al. 2019

Nat Rev Clin Oncol

1,570

1,183

View full text Add to dashboard Cite

show abstract

“…The third report was of a 59‐year‐old male patient with MM and VKHD was observed 16 months after fifth‐line ipilimumab therapy, in which initial symptoms were poliosis and vitiligo, and HLA‐DR4 was detected. The fourth report was of a 61‐year‐old male patient with NSCLC and VKHD was observed two months after first‐line pembrolizumab therapy, in which initial symptoms were ocular pain and auditory change, and HLA‐DR4 was not assessed.…”

Section: Discussionmentioning

confidence: 99%

“…Immune‐related adverse events (irAEs) occur with a certain frequency and Vogt–Koyanagi–Harada disease (VKHD) is a quite rare irAE with only one report in the treatment of NSLC with pembrolizumab monotherapy . In this report, VKHD during chemoimmunotherapy in a patient with NSCLC was successfully treated with corticosteroid.…”

Section: Introductionmentioning

confidence: 89%

Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer

Kurono

Takeda

Kunimatsu

et al. 2020

Respirology Case Reports

View full text Add to dashboard Cite

Vogt–Koyanagi–Harada disease (VKHD) is a rare systemic granulomatous autoimmune disease that affects melanocyte‐rich organs such as eye, inner ear, meninges, skin, and hair. VKHD leads to chronic uveal inflammation accompanied by a decline in visual acuity in some patients when appropriate corticosteroid treatment was not initiated in an early phase. Immune checkpoint inhibitors (ICIs) are widely used in the treatment of several kinds of cancers and chemoimmunotherapy has become the standard of care in the first‐line treatment of non‐small cell lung cancer (NSCLC). While ICIs induce immune‐related adverse events, drug‐induced VKHD is quite rare with only four reports in the ICI monotherapy; three patients with melanoma and one patient with NSCLC. We describe the first case of VKHD during chemoimmunotherapy including pembrolizumab in a patient with NSCLC, which was successfully treated with corticosteroid without any sequela.

show abstract

“…17 Patients suffering from VKH-like syndrome were initially diagnosed with mostly metastatic melanoma 25 and a few with nonsmall cell lung cancer. 24…”

Section: Vogt-koyanagi-harada Like Syndromementioning

confidence: 99%

“…It has been reported that CTLA4 or PD‐1 antibodies, or a combination of the two might cause VKH‐like syndrome, as does TIL + IL2 therapy . Patients suffering from VKH‐like syndrome were initially diagnosed with mostly metastatic melanoma and a few with non‐small cell lung cancer …”

Section: Vogt‐koyanagi‐harada Like Syndromementioning

confidence: 99%

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

et al. 2020

View full text Add to dashboard Cite

The increased use of targeted therapy and immune checkpoint inhibitors in cancers has brought new hope of survival to patients with advanced tumors. However, increasing numbers of immune‐related adverse events (irAEs) of these medications have been reported, affecting almost all human organs including the eye. These adverse effects may affect the entire ocular region, including the eyelid, eye lashes, conjunctiva, cornea, uvea, retina and optic nerve, and have thus far been largely ignored by patients and doctors. In this review, we summarize the characteristics of ocular diseases related to irAEs and advise on how to diagnose and manage these diseases. Key points This review will enable clinical oncologists to recognize, diagnose, and manage targeted therapy and immune checkpoint inhibitor‐related ocular adverse events.

show abstract

Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non–Small Cell Lung Cancer

Cited by 21 publications

References 4 publications

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

Contact Info

Product

Resources

About